Similar articles

• Medical progress: Acromegaly.

  Melmed S. Melmed S. N Engl J Med. 2006 Dec 14;355(24):2558-73. doi: 10.1056/NEJMra062453. N Engl J Med. 2006. PMID: 17167139 Review. No abstract available.
• Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.

  van der Lely AJ, Muller A, Janssen JA, Davis RJ, Zib KA, Scarlett JA, Lamberts SW. van der Lely AJ, et al. J Clin Endocrinol Metab. 2001 Feb;86(2):478-81. doi: 10.1210/jcem.86.2.7206. J Clin Endocrinol Metab. 2001. PMID: 11157994
• Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.

  Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ. Trainer PJ, et al. N Engl J Med. 2000 Apr 20;342(16):1171-7. doi: 10.1056/NEJM200004203421604. N Engl J Med. 2000. PMID: 10770982 Clinical Trial.
• Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY.

  Brue T, Castinetti F, Lundgren F, Koltowska-Häggström M, Petrossians P; ACROSTUDY investigators. Brue T, et al. Eur J Endocrinol. 2009 Nov;161 Suppl 1:S11-7. doi: 10.1530/EJE-09-0333. Epub 2009 Aug 14. Eur J Endocrinol. 2009. PMID: 19684051
• Experience with pegvisomant in the treatment of acromegaly.

  Drake WM. Drake WM. Growth Horm IGF Res. 2001 Jun;11 Suppl A:S111-4. doi: 10.1016/s1096-6374(01)80018-6. Growth Horm IGF Res. 2001. PMID: 11527081 Review.